Fiche publication
Date publication
novembre 2018
Journal
Biochimica et biophysica acta. General subjects
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEGIN-COLIN Sylvie
,
Dr FRANCIUS Grégory
,
Dr MERTZ Damien
Tous les auteurs :
Ménard M, Meyer F, Parkhomenko K, Leuvrey C, Francius G, Bégin-Colin S, Mertz D
Lien Pubmed
Résumé
Human serum albumin (HSA) nanoparticles emerge as promising carriers for drug delivery. Among challenges, one important issue is the design of HSA nanoparticles with a low mean size of ca. 50 nm and having a high drug payload. The original strategy developed here is to use sacrificial mesoporous nanosilica templates having a diameter close to 30 nm to drive the protein nanocapsule formation. This new approach ensures first an efficient high drug loading (ca. 30%) of Doxorubicin (DOX) in the porous silica by functionalizing silica with an aminosiloxane layer and then allows the one-step adsorption and the physical cross-linking of HSA by modifying the silica surface with isobutyramide (IBAM) groups. After silica template removal, homogenous DOX-loaded HSA nanocapsules (30-60 nm size) with high drug loading capacity (ca. 88%) are thus formed. Such nanocapsules are shown efficient in multicellular tumor spheroid models (MCTS) of human hepatocarcinoma cells by their significant growth inhibition with respect to controls. Such a new synthesis approach paves the way toward new protein based nanocarriers for drug delivery.
Référence
Biochim Biophys Acta Gen Subj. 2018 Nov 1;:
